CATEGORIES: CMT Summit | Fashion and Products | Featured | Newly Diagnosed | Nutrition | Patient-Focused Research | Pediatrics & CMT | Research | Research and Critical Trials

7 Reasons You Can’t Miss the Nashville CMT Summit

by | Jan 28, 2025 | 0 comments

Mark your calendars for April 24–26, 2025, because the Nashville CMT Summit is bringing the ultimate blend of knowledge, community, and fun! Here are 7 reasons you absolutely need to be there:

Test & Try Mobility Aids: Explore the latest tools to keep you moving with confidence.

Nashville-Themed Welcome Party: Grab your cowboy hat and celebrate in true Music City style!

Pain & Fatigue Support: Discover strategies to feel your best and tackle life head-on.

Join the CMT Wearable Study: Be part of cutting-edge research in wearable technology.

CMT Speed-Friending: Build connections with others in the CMT community—because we’re stronger together.

Prepare for CMT Clinical Trials: Learn about upcoming trials and how you can make an impact.

Donate to the CMT Biobank: Your blood donation could help researchers find the next big breakthrough.

Visit cmtsummit.org for all the details and to register today!

We can’t wait to see you there. Let’s make this summit the best yet!

REGISTER TODAY

Learn more on this topic

Related Blog Posts

A New Mouse Model for Charcot-Marie-Tooth (CMT2)

by | May 27, 2015 | , , | 0 Comments

We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation.

Hot Off the Press – Potential Treatment for CMT1A

by | Mar 9, 2015 | , , | 53 Comments

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news